Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b, Open-Label, Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-98854 in Children and Adolescents With Tourette Syndrome

NCT02256475 is registered in ClinicalTrials.gov with Neurocrine Biosciences as lead sponsor.

NCT NCT02256475
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02256475 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b, Open-Label, Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-98854 in Children and Adolescents With Tourette Syndrome
Lead sponsor
Neurocrine Biosciences
Phase
Phase 1
Overall status
Completed
Start date
September 30, 2014
Completion date
December 31, 2015
Enrollment
36 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

tourette syndrome